Comparison of Silevimig, a Novel Bispecific Anti-Rabies Monoclonal Antibody, with Human Rabies Immunoglobulin for Post-Exposure Prophylaxis: A Phase III, Randomized, Double-Blind, Non-Inferiority Trial

Xiuqing Wang, Jing He, Yongxian Zha, Ya Jiang, Shuzuo Tan, Qinghua Li, Ruichun Zhao, Hong Su, Yuanmo Shi, Zhongliang Yang, Shiming Zhang, Yaling Zhou, Xiang Yi, Raodong Pu, Xi He, Rui Chang, Yinfeng Ma, Yunxia Chen, Guoyu Yang, Youfei Zhang, Yan Yang, Xiaoxiao Li, Mei Li, Sisi Li, Wenmei Bao, Tingkui Li, Xiaoqiang Liu

Open source

DOI: 10.1093/cid/ciag551
Published: 2026-09-21
Container: Clinical Infectious Diseases
Publisher: Oxford University Press (OUP)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/cid/ciag551,
  title = {Comparison of Silevimig, a Novel Bispecific Anti-Rabies Monoclonal Antibody, with Human Rabies Immunoglobulin for Post-Exposure Prophylaxis: A Phase III, Randomized, Double-Blind, Non-Inferiority Trial},
  author = {Xiuqing Wang and Jing He and Yongxian Zha and Ya Jiang and Shuzuo Tan and Qinghua Li and Ruichun Zhao and Hong Su and Yuanmo Shi and Zhongliang Yang and Shiming Zhang and Yaling Zhou and Xiang Yi and Raodong Pu and Xi He and Rui Chang and Yinfeng Ma and Yunxia Chen and Guoyu Yang and Youfei Zhang and Yan Yang and Xiaoxiao Li and Mei Li and Sisi Li and Wenmei Bao and Tingkui Li and Xiaoqiang Liu},
  year = {2026},
  journal = {Clinical Infectious Diseases},
  doi = {10.1093/cid/ciag551},
  url = {https://doi.org/10.1093/cid/ciag551}
}

RIS

TY  - JOUR
TI  - Comparison of Silevimig, a Novel Bispecific Anti-Rabies Monoclonal Antibody, with Human Rabies Immunoglobulin for Post-Exposure Prophylaxis: A Phase III, Randomized, Double-Blind, Non-Inferiority Trial
AU  - Xiuqing Wang
AU  - Jing He
AU  - Yongxian Zha
AU  - Ya Jiang
AU  - Shuzuo Tan
AU  - Qinghua Li
AU  - Ruichun Zhao
AU  - Hong Su
AU  - Yuanmo Shi
AU  - Zhongliang Yang
AU  - Shiming Zhang
AU  - Yaling Zhou
AU  - Xiang Yi
AU  - Raodong Pu
AU  - Xi He
AU  - Rui Chang
AU  - Yinfeng Ma
AU  - Yunxia Chen
AU  - Guoyu Yang
AU  - Youfei Zhang
AU  - Yan Yang
AU  - Xiaoxiao Li
AU  - Mei Li
AU  - Sisi Li
AU  - Wenmei Bao
AU  - Tingkui Li
AU  - Xiaoqiang Liu
PY  - 2026
JO  - Clinical Infectious Diseases
DO  - 10.1093/cid/ciag551
UR  - https://doi.org/10.1093/cid/ciag551
ER  -

APA

Wang, X., He, J., Zha, Y., Jiang, Y., Tan, S., Li, Q., Zhao, R., Su, H., Shi, Y., Yang, Z., Zhang, S., Zhou, Y., Yi, X., Pu, R., He, X., Chang, R., Ma, Y., Chen, Y., Yang, G., Zhang, Y., Yang, Y., Li, X., Li, M., Li, S., Bao, W., Li, T., & Liu, X. (2026). Comparison of Silevimig, a Novel Bispecific Anti-Rabies Monoclonal Antibody, with Human Rabies Immunoglobulin for Post-Exposure Prophylaxis: A Phase III, Randomized, Double-Blind, Non-Inferiority Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag551

Source records

crossref · retrieved 2026-09-26T11:29:00.871Z